|
시장보고서
상품코드
1786786
세계의 항진균제 시장 : 규모, 점유율, 동향, 산업 분석 보고서 - 약품 클래스별, 적응증별, 제형별, 유통 채널별, 지역별 시장 예측(2025-2034년)Antifungal Drugs Market Size, Share, Trend, Industry Analysis Report By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others), By Indication, By Dosage Form, By Distribution Channel, By Region - Market Forecast, 2025-2034 |
||||||
Polaris Market Research의 최근 조사에 따르면 항진균제 시장 규모는 2034년까지 232억 2,000만 달러에 이를 것으로 예측됩니다. 이 보고서는 현재 시장 역학을 상세하게 파악하고 미래 시장 성장에 대한 분석을 제공합니다.
항진균제 시장은 피부, 손톱, 점막 및 내장에 영향을 미치는 광범위한 진균 감염을 치료하는 데 사용되는 의약품의 개발, 생산 및 유통에 중점을 둡니다. 특히 암 치료 중이나 장기 이식 중 만성 질환을 앓고 있는 면역 결핍 환자들 사이에서 진균증이 증가하고 있는 것이 효과적인 항진균 요법에 대한 안정된 수요를 견인하고 있습니다.
원내 진균 감염 증가로 의료 제공업체는 항진균제를 예방 및 치료 프로토콜에 통합해야 합니다. 업계 동향은 표적 요법, 약물 전달 시스템의 개선, 내성 및 독성 문제를 극복하기 위해 새로운 제제의 사용으로의 변화를 보여줍니다. 국소 투여, 경구 투여 및 정맥 내 투여와 같은 전달 플랫폼의 끊임없는 기술 혁신은 환자의 충격 및 치료 효과를 향상시킵니다. 제약 회사는 또한 내성 균주 및 침습성 감염을 표적으로 하는 차세대 항진균제에 투자하고 있습니다.
진단 능력의 확대는 조기 발견을 가능하게 하고, 치료 성적의 향상과 처방량 증가에 기여하고 있습니다. 현재 최적의 치료법이 확립되어 있지 않은 특정 적응증에 대한 항진균제의 개발이나 충분한 의료 서비스가 제공되지 않은 신흥국 시장에서의 접근 확대에도 치료 기회가 있습니다. 각 회사는 재제 및 합제와 같은 기존 약물의 수명 주기 관리에 점점 더 많은 노력을 기울이고 있습니다. 게다가, 항균제 내성에 대처하기 위한 세계 헬스 이니셔티브는 자금 제공과 파트너십의 여지를 창출하고, 항진균제 영역을 임상 연구의 활발한 영역으로 하고 있습니다. 기술과 치료법의 진보에 더해, 환자의 안전성이 중시되게 된 것으로, 항진균제 시장은 경쟁과 기술 혁신에 견인되는 양상을 나타내고 있습니다.
항진균제 시장 보고서 하이라이트
약물 등급별로는 아졸계 약물이 광역 스펙트럼 활성과 표재성 및 전신성 진균 감염증의 치료에 있어서 확립된 임상 효과에 의해 2024년의 매출 점유율의 48%를 차지했습니다.
적응증별로는 칸디다증이 면역 결핍환자 및 입원환자 사이에서 높은 유병률을 보였기 때문에 2024년 최대 판매 점유율을 차지했습니다.
2024년에는 북미가 세계 항진균제 시장 수익의 약 41%를 차지했는데, 이는 진보된 의료 인프라의 존재, 면역억제 요법의 빈번한 사용, 노인 인구 증가 때문입니다.
아시아태평양은 의료 접근성이 급속히 개선되고 진균 감염에 대한 인식이 높아짐에 따라 예측 기간 동안 가장 높은 CAGR을 나타낼 것으로 예측됩니다.
세계 주요 기업으로는 Abbott, Astellas Pharma, Inc., Bayer AG, Enzon Pharmaceuticals, Inc., Glenmark, GSK plc, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi 등이 있습니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 항진균제 시장 인사이트
- 시장 현황
- 항진균제 시장 역학
- 성장 촉진요인 및 기회
- 고령화 인구 증가
- 진균 감염증의 만연
- 성장 억제요인 및 과제
- 제품의 고비용
- 성장 촉진요인 및 기회
- PESTEL 분석
- 항진균제 시장의 힘 평가 동향
- 밸류체인 분석
제5장 항진균제 시장 : 약제 클래스별
- 주요 조사 결과
- 서문
- 아졸
- 에키노캔디
- 폴리엔
- 알릴아민
- 기타
제6장 항진균제 시장 : 적응증별
- 주요 조사 결과
- 서문
- 피부사상균증
- 아스페르길루스증
- 칸디다증
- 기타
제7장 항진균제 시장 : 제형별
- 주요 조사 결과
- 서문
- 경구약
- 연고
- 분말
- 기타
제8장 항진균제 시장 : 유통 채널별
- 주요 조사 결과
- 서문
- 병원 약국
- 소매 약국
- 기타
제9장 항진균제 시장 : 지역별
- 주요 조사 결과
- 서문
- 항진균제 시장 분석 : 지역별(2020-2034년)
- 북미
- 북미 : 약제 클래스별(2020-2034년)
- 북미 : 적응증별(2020-2034년)
- 북미 : 유통 채널별(2020-2034년)
- 북미 : 제형별(2020-2034년)
- 미국
- 캐나다
- 유럽
- 유럽 : 약제 클래스별(2020-2034년)
- 유럽 : 적응증별(2020-2034년)
- 유럽 : 유통 채널별(2020-2034년)
- 유럽 : 제형별(2020-2034년)
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 약제 클래스별, 2020년-2034년
- 아시아태평양 : 적응증별(2020-2034년)
- 아시아태평양 : 유통 채널별(2020-2034년)
- 아시아태평양 : 제형별(2020-2034년)
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 약제 클래스별(2020-2034년)
- 중동 및 아프리카 : 적응증별(2020-2034년)
- 중동 및 아프리카 : 유통 채널별(2020-2034년)
- 중동 및 아프리카 : 제형별(2020-2034년)
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 남아프리카
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 약제 클래스별(2020-2034년)
- 라틴아메리카 : 적응증별(2020-2034년)
- 라틴아메리카 : 유통 채널별(2020-2034년)
- 라틴아메리카 : 제형별(2020-2034년)
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제10장 경쟁 구도
- 확대 및 인수 분석
- 확대
- 인수
- 제휴, 협업, 합의 및 공개
제11장 기업 프로파일
- Abbott
- Astellas Pharma, Inc.
- Bayer AG
- Enzon Pharmaceuticals, Inc.
- Glenmark
- GSK plc
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc
- Sanofi
The antifungal drugs market size is expected to reach USD 23.22 billion by 2034, according to a new study by Polaris Market Research. The report "Antifungal Drugs Market Size, Share, Trend, Industry Analysis Report By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others), By Indication, By Dosage Form, By Distribution Channel, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The antifungal drugs market focuses on the development, production, and distribution of medications used to treat a wide range of fungal infections affecting the skin, nails, mucous membranes, and internal organs. Rising cases of fungal diseases, particularly among immunocompromised individuals undergoing cancer treatments, organ transplantation, or suffering from chronic illnesses, are driving steady demand for effective antifungal therapies.
The increasing incidence of hospital-acquired fungal infections is pushing healthcare providers to incorporate antifungal agents into preventive and treatment protocols. Industry trends indicate a shift toward the use of targeted therapies, improved drug delivery systems, and novel formulations designed to overcome resistance and toxicity issues. Continuous innovation in topical, oral, and intravenous delivery platforms is enhancing patient adherence and treatment efficacy. Pharmaceutical companies are also investing in new-generation antifungal agents that target resistant strains and invasive infections.
Expanding diagnostic capabilities are enabling early detection, which improves outcomes and fuels prescription volumes. Opportunities lie in developing antifungal solutions for specific indications that currently lack optimal treatments, as well as expanding access in underserved healthcare markets. Companies are increasingly focusing on the lifecycle management of established drugs, including reformulation and fixed-dose combinations. Additionally, global health initiatives aimed at tackling antimicrobial resistance are creating room for funding and partnerships, making the antifungal space an active area for clinical research. The growing emphasis on patient safety, combined with technological and therapeutic advancements, continues to shape a competitive and innovation-driven antifungal drug landscape.
Antifungal Drugs Market Report Highlights
By drug class, the azoles drug segment accounted for ~48% of the revenue share in 2024 due to their broad-spectrum activity and established clinical effectiveness in treating both superficial and systemic fungal infections.
Based on indication, the candidiasis segment held the largest revenue share in 2024 due to its high prevalence among immunocompromised and hospitalized patients.
In 2024, North America accounted for a ~41% share of the global antifungal drugs market revenue due to the strong presence of advanced healthcare infrastructure, frequent use of immunosuppressive therapies, and a growing elderly population.
The market in Asia Pacific is expected to register the highest CAGR during the forecast period due to rapid improvements in healthcare access and growing awareness of fungal infections.
A few global key players include Abbott; Astellas Pharma, Inc.; Bayer AG; Enzon Pharmaceuticals, Inc.; Glenmark; GSK plc; Merck & Co., Inc.; Novartis AG; Pfizer, Inc.; and Sanofi.
Polaris Market Research has segmented the antifungal drugs market report on the basis of drug class, indication, dosage form, distribution channel, and region:
By Drug Class Outlook (Revenue, USD Billion, 2020-2034)
Azoles
Echinocandins
Polyenes
Allylamines
Others
By Indication Outlook (Revenue, USD Billion, 2020-2034)
Dermatophytosis
Aspergillosis
Candidiasis
Others
By Dosage Form Outlook (Revenue, USD Billion, 2020-2034)
Oral Drugs
Ointments
Powders
Others
By Distribution Channel Outlook (Revenue, USD Billion, 2020-2034)
Hospital Pharmacies
Retail Pharmacies
Others
By Regional Outlook (Revenue, USD Billion, 2020-2034)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Vietnam
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Antifungal Drugs Market Insights
- 4.1. Antifungal Drugs Market - Market Snapshot
- 4.2. Antifungal Drugs Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Growing Geriatric Population
- 4.2.1.2. Rising Prevalence of Fungal Infections
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High costs of the products
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Antifungal Drugs Market Power Rating Trends
- 4.6. Value Chain Analysis
5. Antifungal Drugs Market, by Drug Class
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Antifungal Drugs Market, by Drug Class, 2020-2034 (USD Billion)
- 5.3. Azoles
- 5.3.1. Antifungal Drugs Market, by Azoles, by Region, 2020-2034 (USD Billion)
- 5.4. Echinocandins
- 5.4.1. Antifungal Drugs Market, by Echinocandins, by Region, 2020-2034 (USD Billion)
- 5.5. Polyenes
- 5.5.1. Antifungal Drugs Market, by Polyenes, by Region, 2020-2034 (USD Billion)
- 5.6. Allylamines
- 5.6.1. Antifungal Drugs Market, by Allylamines, by Region, 2020-2034 (USD Billion)
- 5.7. Others
- 5.7.1. Antifungal Drugs Market, by Others, by Region, 2020-2034 (USD Billion)
6. Antifungal Drugs Market, by Indication
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 6.3. Dermatophytosis
- 6.3.1. Antifungal Drugs Market, by Dermatophytosis, by Region, 2020-2034 (USD Billion)
- 6.4. Aspergillosis
- 6.4.1. Antifungal Drugs Market, by Aspergillosis, by Region, 2020-2034 (USD Billion)
- 6.5. Candidiasis
- 6.5.1. Antifungal Drugs Market, by Candidiasis, by Region, 2020-2034 (USD Billion)
- 6.6. Others
- 6.6.1. Antifungal Drugs Market, by Others, by Region, 2020-2034 (USD Billion)
7. Antifungal Drugs Market, by Dosage Form
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 7.3. Oral Drugs
- 7.3.1. Antifungal Drugs Market, by Oral Drugs, by Region, 2020-2034 (USD Billion)
- 7.4. Ointments
- 7.4.1. Antifungal Drugs Market, by Ointments, by Region, 2020-2034 (USD Billion)
- 7.5. Powders
- 7.5.1. Antifungal Drugs Market, by Powders, by Region, 2020-2034 (USD Billion)
- 7.6. Others
- 7.6.1. Antifungal Drugs Market, by Others, by Region, 2020-2034 (USD Billion)
8. Antifungal Drugs Market, by Distribution Channel
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.3. Hospital Pharmacies
- 8.3.1. Antifungal Drugs Market, by Hospital Pharmacies, by Region, 2020-2034 (USD Billion)
- 8.4. Retail Pharmacies
- 8.4.1. Antifungal Drugs Market, by Retail Pharmacies, by Region, 2020-2034 (USD Billion)
- 8.5. Others
- 8.5.1. Antifungal Drugs Market, by Others, by Region, 2020-2034 (USD Billion)
9. Antifungal Drugs Market, by Geography
- 9.1. Key Findings
- 9.2. Introduction
- 9.2.1. Antifungal Drugs Market Assessment, By Geography, 2020-2034 (USD Billion)
- 9.3. Antifungal Drugs Market - North America
- 9.3.1. North America: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.3.2. North America: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.3.3. North America: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.3.4. North America: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.3.5. Antifungal Drugs Market - US
- 9.3.5.1. US: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.3.5.2. US: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.3.5.3. US: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.3.5.4. US: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.3.6. Antifungal Drugs Market - Canada
- 9.3.6.1. Canada: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.3.6.2. Canada: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.3.6.3. Canada: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.3.6.4. Canada: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.4. Antifungal Drugs Market - Europe
- 9.4.1. Europe: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.4.2. Europe: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.4.3. Europe: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.4.4. Europe: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.4.5. Antifungal Drugs Market - UK
- 9.4.5.1. UK: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.4.5.2. UK: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.4.5.3. UK: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.4.5.4. UK: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.4.6. Antifungal Drugs Market - France
- 9.4.6.1. France: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.4.6.2. France: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.4.6.3. France: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.4.6.4. France: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.4.7. Antifungal Drugs Market - Germany
- 9.4.7.1. Germany: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.4.7.2. Germany: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.4.7.3. Germany: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.4.7.4. Germany: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.4.8. Antifungal Drugs Market - Italy
- 9.4.8.1. Italy: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.4.8.2. Italy: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.4.8.3. Italy: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.4.8.4. Italy: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.4.9. Antifungal Drugs Market - Spain
- 9.4.9.1. Spain: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.4.9.2. Spain: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.4.9.3. Spain: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.4.9.4. Spain: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.4.10. Antifungal Drugs Market - Netherlands
- 9.4.10.1. Netherlands: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.4.10.2. Netherlands: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.4.10.3. Netherlands: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.4.10.4. Netherlands: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.4.11. Antifungal Drugs Market - Russia
- 9.4.11.1. Russia: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.4.11.2. Russia: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.4.11.3. Russia: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.4.11.4. Russia: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.4.12. Antifungal Drugs Market - Rest of Europe
- 9.4.12.1. Rest of Europe: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.4.12.2. Rest of Europe: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.4.12.3. Rest of Europe: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.4.12.4. Rest of Europe: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.5. Antifungal Drugs Market - Asia Pacific
- 9.5.1. Asia Pacific: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.5.2. Asia Pacific: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.5.3. Asia Pacific: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.5.4. Asia Pacific: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.5.5. Antifungal Drugs Market - China
- 9.5.5.1. China: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.5.5.2. China: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.5.5.3. China: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.5.5.4. China: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.5.6. Antifungal Drugs Market - India
- 9.5.6.1. India: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.5.6.2. India: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.5.6.3. India: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.5.6.4. India: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.5.7. Antifungal Drugs Market - Malaysia
- 9.5.7.1. Malaysia: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.5.7.2. Malaysia: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.5.7.3. Malaysia: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.5.7.4. Malaysia: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.5.8. Antifungal Drugs Market - Japan
- 9.5.8.1. Japan: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.5.8.2. Japan: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.5.8.3. Japan: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.5.8.4. Japan: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.5.9. Antifungal Drugs Market - Indonesia
- 9.5.9.1. Indonesia: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.5.9.2. Indonesia: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.5.9.3. Indonesia: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.5.9.4. Indonesia: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.5.10. Antifungal Drugs Market - South Korea
- 9.5.10.1. South Korea: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.5.10.2. South Korea: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.5.10.3. South Korea: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.5.10.4. South Korea: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.5.11. Antifungal Drugs Market - Australia
- 9.5.11.1. Australia: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.5.11.2. Australia: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.5.11.3. Australia: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.5.11.4. Australia: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.5.12. Antifungal Drugs Market - Rest of Asia Pacific
- 9.5.12.1. Rest of Asia Pacific: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.5.12.2. Rest of Asia Pacific: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.5.12.3. Rest of Asia Pacific: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.5.12.4. Rest of Asia Pacific: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.6. Antifungal Drugs Market - Middle East & Africa
- 9.6.1. Middle East & Africa: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.6.2. Middle East & Africa: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.6.3. Middle East & Africa: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.6.4. Middle East & Africa: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.6.5. Antifungal Drugs Market - Saudi Arabia
- 9.6.5.1. Saudi Arabia: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.6.5.2. Saudi Arabia: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.6.5.3. Saudi Arabia: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.6.5.4. Saudi Arabia: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.6.6. Antifungal Drugs Market - UAE
- 9.6.6.1. UAE: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.6.6.2. UAE: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.6.6.3. UAE: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.6.6.4. UAE: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.6.7. Antifungal Drugs Market - Israel
- 9.6.7.1. Israel: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.6.7.2. Israel: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.6.7.3. Israel: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.6.7.4. Israel: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.6.8. Antifungal Drugs Market - South Africa
- 9.6.8.1. South Africa: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.6.8.2. South Africa: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.6.8.3. South Africa: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.6.8.4. South Africa: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.6.9. Antifungal Drugs Market - Rest of Middle East & Africa
- 9.6.9.1. Rest of Middle East & Africa: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.6.9.2. Rest of Middle East & Africa: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.6.9.3. Rest of Middle East & Africa: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.6.9.4. Rest of Middle East & Africa: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.7. Antifungal Drugs Market - Latin America
- 9.7.1. Latin America: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.7.2. Latin America: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.7.3. Latin America: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.7.4. Latin America: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.7.5. Antifungal Drugs Market - Mexico
- 9.7.5.1. Mexico: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.7.5.2. Mexico: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.7.5.3. Mexico: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.7.5.4. Mexico: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.7.6. Antifungal Drugs Market - Brazil
- 9.7.6.1. Brazil: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.7.6.2. Brazil: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.7.6.3. Brazil: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.7.6.4. Brazil: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.7.7. Antifungal Drugs Market - Argentina
- 9.7.7.1. Argentina: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.7.7.2. Argentina: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.7.7.3. Argentina: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.7.7.4. Argentina: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
- 9.7.8. Antifungal Drugs Market - Rest of Latin America
- 9.7.8.1. Rest of Latin America: Antifungal Drugs Market, By Drug Class, 2020-2034 (USD Billion)
- 9.7.8.2. Rest of Latin America: Antifungal Drugs Market, By Indication, 2020-2034 (USD Billion)
- 9.7.8.3. Rest of Latin America: Antifungal Drugs Market, by Distribution Channel, 2020-2034 (USD Billion)
- 9.7.8.4. Rest of Latin America: Antifungal Drugs Market, by Dosage Form, 2020-2034 (USD Billion)
10. Competitive Landscape
- 10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
- 10.2. Partnerships/Collaborations/Agreements/Exhibitions
11. Company Profiles
- 11.1. Abbott
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
- 11.2. Astellas Pharma, Inc.
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
- 11.3. Bayer AG
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
- 11.4. Enzon Pharmaceuticals, Inc.
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
- 11.5. Glenmark
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
- 11.6. GSK plc
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
- 11.7. Merck & Co., Inc.
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
- 11.8. Novartis AG
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
- 11.9. Pfizer, Inc
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
- 11.10. Sanofi
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development
